Hepatic Veno-Occlusive Disease
"Hepatic Veno-Occlusive Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
| Descriptor ID |
D006504
|
| MeSH Number(s) |
C06.552.360 C14.907.460
|
| Concept/Terms |
Hepatic Veno-Occlusive Disease- Hepatic Veno-Occlusive Disease
- Disease, Hepatic Veno-Occlusive
- Hepatic Veno-Occlusive Diseases
- Sinusoidal Obstruction Syndrome
- Syndrome, Sinusoidal Obstruction
- Hepatic Veno Occlusive Disease
- Veno-Occlusive Disease, Hepatic
- Veno Occlusive Disease, Hepatic
|
Below are MeSH descriptors whose meaning is more general than "Hepatic Veno-Occlusive Disease".
Below are MeSH descriptors whose meaning is more specific than "Hepatic Veno-Occlusive Disease".
This graph shows the total number of publications written about "Hepatic Veno-Occlusive Disease" by people in this website by year, and whether "Hepatic Veno-Occlusive Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 1 | 4 |
| 2003 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 3 | 1 | 4 |
| 2022 | 2 | 0 | 2 |
| 2023 | 2 | 0 | 2 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepatic Veno-Occlusive Disease" by people in Profiles.
-
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood Cancer J. 2024 08 07; 14(1):129.
-
Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions. Cancer. 2024 Nov 01; 130(21):3631-3646.
-
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv. 2024 03 12; 8(5):1128-1136.
-
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 02 01; 143(5):417-421.
-
Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation. JCI Insight. 2023 05 22; 8(10).
-
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun; 10(6):e433-e444.
-
Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 01; 70(1):e29939.
-
Sinusoidal Obstruction Syndrome of the Liver Associated With 6-Mercaptopurine During Maintenance in a Child With T-cell Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2023 01 01; 45(1):e121-e123.
-
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol. 2020 10 15; 13(1):137.
-
Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 ?Mol?min. A historically controlled clinical trial. Hematol Oncol. 2020 Dec; 38(5):773-781.